Event-Driven Stocks

FATE THERAPEUTICS INC

FATENasdaq

Healthcare · Biological Products, (No Diagnostic Substances) · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 1 good● 4 warningdetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$6.6M$13.6M$63.5M$96.3M$55.8M$31.4M
Operating income−$147.7M−$210.3M−$190.5M−$308.4M−$217.0M−$128.1M
Net income−$136.3M−$186.3M−$160.9M−$281.7M−$212.2M−$173.4M
Total assets$318.9M$440.7M$506.2M$705.6M$921.5M$622.5M
Total liabilities——————
Equity$207.2M$318.7M$368.4M$483.9M$678.8M$384.4M
EPS (diluted)$-1.15$-1.64$-1.64$-2.91$-2.24$-2.10
Shares out.114.6M99.2M98.2M96.4M93.8M75.9M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−2222.4%
Net margin
−2051.1%
Return on equity
−65.8%
Return on assets
−42.7%
Return on capital (ROCE)
−52.2%
Liabilities / assets
—
Debt / equity
—
Book value / share
$1.81
Revenue growth (YoY)
−51.2%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Accruals / assets
−9.5%clean
Piotroski F-Score
1/8weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
47
/ 100
Profitability 0Growth 0Catalyst 67Earnings quality 67Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

● 4 warning● 1 good
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Revenue declined year-over-year
  • Negative operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20269.7M2.0-5.1%
Apr 30, 202610.3M9.3-0.2%
Apr 15, 202610.3M8.2+4.2%
Mar 31, 20269.9M6.6+5.8%
Mar 13, 20269.3M6.6-2.6%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.